ID Source | ID |
---|---|
PubMed CID | 42611 |
CHEMBL ID | 2106672 |
SCHEMBL ID | 123268 |
MeSH ID | M0200098 |
Synonym |
---|
D02771 |
57938-82-6 |
adinazolam mesylate (usan) |
adinazolam mesylate |
adinazolam mesilate |
CHEMBL2106672 |
u-41123f |
adinazolam methanesulfonate |
adinazolam monomethanesulfonate |
u 41,123f |
unii-nt8s62a727 |
u-41,123f |
nt8s62a727 , |
4h-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepine-1-methanamine, 8-chloro-n,n-dimethyl-6-phenyl-, monomethanesulfonate |
adinazolam mesylate [usan] |
8-chloro-1-((dimethylamino)methyl)-6-phenyl-4h-s-triazolo(4,3-a)(1,4)benzodiazepine monomethanesulfonate |
adinazolam mesilate [mart.] |
4h-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepine-1-methanamine, 8-chloro-n,n-dimethyl-6-phenyl-, monomethanesulphonate |
8-chloro-1-((dimethylamino)methyl)-6-phenyl-4h-s-triazolo(4,3-a)(1,4)benzodiazepine monomethanesulphonate |
8-chloro-1-[(dimethylamino)methyl]-6-phenyl-4h-s-triazolo[4,3-a][1,4]benzodiazepine monomethanesulfonate |
adinazolam methanesulfonate [mi] |
SCHEMBL123268 |
DTXSID00206641 |
Q27285045 |
1-(8-chloro-6-phenyl-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-1-yl)-n,n-dimethylmethanamine;methanesulfonic acid |
AKOS040759485 |
Excerpt | Reference | Relevance |
---|---|---|
" In vivo/in vitro relationships from two bioavailability studies were thoroughly evaluated." | ( In vitro and in vivo evaluation of whole and half tablets of sustained-release adinazolam mesylate. Borin, MT; Cooper, AM; Fleishaker, JC; Skoug, JW, 1991) | 0.51 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 9 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.05) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 1 (11.11%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (88.89%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |